Literature DB >> 19633761

Multiple sclerosis registry in Germany: results of the extension phase 2005/2006.

Peter Flachenecker1, Kristin Stuke, Wolfgang Elias, Matthias Freidel, Judith Haas, Dorothea Pitschnau-Michel, Sebastian Schimrigk, Uwe K Zettl, Peter Rieckmann.   

Abstract

INTRODUCTION: In 2001, a nationwide multiple sclerosis (MS) registry was initiated in Germany under the auspices of the German MS Society, (DMSG Bundesverband e.V.). The project aimed at collecting epidemiological data and information on health care provision for MS patients in Germany.
METHODS: After a 2-year pilot phase, the original entry mask was modified, and new centers were recruited, resulting in the registration of a total of 5821 patients in 2005 and 2006. Following a 2 stage quality control process, standardized data sets for 5445 patients (93.5%) were able to be analyzed.
RESULTS: Mean duration from onset of disease to diagnosis was 3.5 years. More than 70% of patients received immunomodulatory drugs, whereas symptomatic treatments were less commonly administered. The number of participating centers as of 31 December 2006 was 57 (29 neurological hospitals, 11 rehabilitation units, 13 specialized practitioners, and 4 regional MS centers). DISCUSSION: The MS registry provides valuable data on patterns of care for MS patients in Germany, and may help to improve service provision and overall quality of life for these patients.

Entities:  

Keywords:  MS registry; ability to work; database mangagement system; drug therapy; epidemiology; multiple sclerosis

Year:  2008        PMID: 19633761      PMCID: PMC2696719          DOI: 10.3238/arztebl.2008.0113

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


  20 in total

Review 1.  [MS Therapy Consensus Group. Immunomodulating staged therapy of multiple sclerosis].

Authors: 
Journal:  Nervenarzt       Date:  1999-04       Impact factor: 1.214

2.  [MS registry in Germany--design and first results of the pilot phase].

Authors:  P Flachenecker; U K Zettl; U Götze; J Haas; S Schimrigk; W Elias; M Pette; M Eulitz; M Hennig; J Bertram; R Hollweck; A Neiss; M Daumer; D Pitschnau-Michel; P Rieckmann
Journal:  Nervenarzt       Date:  2005-08       Impact factor: 1.214

3.  Factors related to employment status changes in individuals with multiple sclerosis.

Authors:  Megan M Smith; Peter A Arnett
Journal:  Mult Scler       Date:  2005-10       Impact factor: 6.312

4.  Disability progression in multiple sclerosis is slower than previously reported.

Authors:  Helen Tremlett; Donald Paty; Virginia Devonshire
Journal:  Neurology       Date:  2006-01-24       Impact factor: 9.910

5.  Changes in the ascertainment of multiple sclerosis.

Authors:  R A Marrie; G Cutter; T Tyry; O Hadjimichael; D Campagnolo; T Vollmer
Journal:  Neurology       Date:  2005-10-11       Impact factor: 9.910

6.  Impairment, disability, and handicap in multiple sclerosis: a population-based study in Olmsted County, Minnesota.

Authors:  M Rodriguez; A Siva; J Ward; K Stolp-Smith; P O'Brien; L Kurland
Journal:  Neurology       Date:  1994-01       Impact factor: 9.910

7.  Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society.

Authors:  T Henze; P Rieckmann; K V Toyka
Journal:  Eur Neurol       Date:  2006-09-08       Impact factor: 1.710

8.  Treatment patterns of multiple sclerosis patients: a comparison of veterans and non-veterans using the NARCOMS registry.

Authors:  Albert C Lo; Olympia Hadjimichael; Timothy L Vollmer
Journal:  Mult Scler       Date:  2005-02       Impact factor: 6.312

9.  Factors influencing work retention for people with multiple sclerosis: cross-sectional studies using qualitative and quantitative methods.

Authors:  Rory J O'Connor; Stefan J Cano; Lluis Ramió i Torrentà; Alan J Thompson; E Diane Playford
Journal:  J Neurol       Date:  2005-05-20       Impact factor: 4.849

Review 10.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".

Authors:  Chris H Polman; Stephen C Reingold; Gilles Edan; Massimo Filippi; Hans-Peter Hartung; Ludwig Kappos; Fred D Lublin; Luanne M Metz; Henry F McFarland; Paul W O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Brian G Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2005-12       Impact factor: 10.422

View more
  24 in total

1.  Headache in the course of multiple sclerosis: a prospective study.

Authors:  Marcel Gebhardt; Peter Kropp; Frank Hoffmann; Uwe K Zettl
Journal:  J Neural Transm (Vienna)       Date:  2018-11-30       Impact factor: 3.575

2.  [Central sleep apnea in multiple sclerosis].

Authors:  A Steffen; J Hagenah; B Wollenberg; N Brüggemann
Journal:  HNO       Date:  2010-04       Impact factor: 1.284

Review 3.  Immunosuppression in clinical practice: approaches to individualized therapy.

Authors:  Andrew Chan; Olaf Stüve; Nicolas von Ahsen
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

4.  [Epidemiology of multiple sclerosis in Germany: regional differences and drug prescription in the claims data of the statutory health insurance].

Authors:  G Petersen; R Wittmann; V Arndt; D Göpffarth
Journal:  Nervenarzt       Date:  2014-08       Impact factor: 1.214

Review 5.  [Real-world evidence : Benefits and limitations in multiple sclerosis research].

Authors:  T Ziemssen; D Rothenbacher; J Kuhle; T Berger
Journal:  Nervenarzt       Date:  2017-10       Impact factor: 1.214

6.  Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany.

Authors:  Anke Stroet; Claudia Hemmelmann; Michaela Starck; Uwe Zettl; Jan Dörr; Paul Friedemann; Friedmann Paul; Peter Flachenecker; Vinzenz Fleischer; Frauke Zipp; Holger Nückel; Bernd C Kieseier; Andreas Ziegler; Ralf Gold; Andrew Chan
Journal:  Ther Adv Neurol Disord       Date:  2012-03       Impact factor: 6.570

7.  [Pharmaceutical prescription for multiple sclerosis : evaluation of pharmaceutical consumption at private health insurance].

Authors:  F Wild
Journal:  Nervenarzt       Date:  2013-02       Impact factor: 1.214

8.  Treatment of multiple sclerosis in Germany: an analysis based on claims data of more than 30,000 patients.

Authors:  Roland Windt; Gerd Glaeske; Falk Hoffmann
Journal:  Int J Clin Pharm       Date:  2013-10-09

Review 9.  National MS registries.

Authors:  Peter Flachenecker; Kristin Stuke
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

10.  Muscle rupture caused by exacerbated spasticity in a patient with multiple sclerosis.

Authors:  Robert Patejdl; Alexander Winkelmann; Reiner Benecke; Uwe Klaus Zettl
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.